- Home
- BATRA vs PTGX Comparison
BATRA vs PTGX Comparison
Compare BATRA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATRA
- PTGX
- Stock Information
- Founded
- BATRA 1991
- PTGX 2006
- Country
- BATRA United States
- PTGX United States
- Employees
- BATRA N/A
- PTGX N/A
- Industry
- BATRA Broadcasting
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- BATRA Industrials
- PTGX Health Care
- Exchange
- BATRA Nasdaq
- PTGX Nasdaq
- Market Cap
- BATRA 2.6B
- PTGX 2.8B
- IPO Year
- BATRA N/A
- PTGX 2016
- Fundamental
- Price
- BATRA $43.49
- PTGX $42.97
- Analyst Decision
- BATRA Strong Buy
- PTGX Strong Buy
- Analyst Count
- BATRA 2
- PTGX 8
- Target Price
- BATRA $56.50
- PTGX $66.50
- AVG Volume (30 Days)
- BATRA 48.7K
- PTGX 1.0M
- Earning Date
- BATRA 05-12-2025
- PTGX 05-06-2025
- Dividend Yield
- BATRA N/A
- PTGX N/A
- EPS Growth
- BATRA N/A
- PTGX N/A
- EPS
- BATRA N/A
- PTGX 0.86
- Revenue
- BATRA $662,748,000.00
- PTGX $207,801,000.00
- Revenue This Year
- BATRA $7.24
- PTGX N/A
- Revenue Next Year
- BATRA $5.65
- PTGX $7.13
- P/E Ratio
- BATRA N/A
- PTGX $49.82
- Revenue Growth
- BATRA 3.45
- PTGX N/A
- 52 Week Low
- BATRA $38.67
- PTGX $24.22
- 52 Week High
- BATRA $46.65
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- BATRA 53.55
- PTGX 43.08
- Support Level
- BATRA $43.21
- PTGX $41.29
- Resistance Level
- BATRA $44.09
- PTGX $46.12
- Average True Range (ATR)
- BATRA 0.75
- PTGX 1.83
- MACD
- BATRA 0.07
- PTGX -0.19
- Stochastic Oscillator
- BATRA 60.98
- PTGX 27.81
About BATRA Atlanta Braves Holdings Inc. Series A
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.